Irinotecan Hydrochloride
FDA-approved product (injectable, injection), marketed as Camptosar, Irinotecan Hydrochloride, Onivyde.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Adenocarcinoma
- Cancer
- Carcinoma
- Malignant Pancreatic Neoplasm
- Neoplasm
- Pancreatic carcinoma
- Pancreatic neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Topoisomerase 1 (top1) inhibitors
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA70.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae54.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis64.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Irinotecan Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
- Ozanimod HydrochlorideExisting use: Multiple sclerosis, Relapsing-remitting multiple sclerosis, Ulcerative colitis66.8% AI-predicted activityagainst MRSA7 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
NCT00033657 · start 2002-08-15
Registered record
- Registry ID
- NCT00033657
- Conditions
- Esophageal Cancer; Gastric Cancer
- Interventions
- cisplatin; irinotecan hydrochloride; paclitaxel; conventional surgery; radiation therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2002-08-15
- Completion
- 2009-10
- Enrolment
- 97
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEsophageal Cancer; Gastric CancerInterventioncisplatin; irinotecan hydrochloride; paclitaxel; conventional surgery +1 morePhasePhase 2Registry statusCompletedImatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00248482 · start 2002-02
Registered record
- Registry ID
- NCT00248482
- Conditions
- Lung Cancer
- Interventions
- Cisplatin; Gleevec™; irinotecan
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2002-02
- Completion
- 2008-01
- Enrolment
- 6
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLung CancerInterventionCisplatin; Gleevec™; irinotecanPhasePhase 2Registry statusCompletedZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
NCT00030524 · start 2002-01
Registered record
- Registry ID
- NCT00030524
- Conditions
- Colorectal Cancer
- Interventions
- gefitinib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2002-01
- Completion
- 2003-09
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionColorectal CancerInterventiongefitinibPhasePhase 2Registry statusCompletedZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer
NCT00026364 · start 2001-11
Registered record
- Registry ID
- NCT00026364
- Conditions
- Colorectal Cancer
- Interventions
- fluorouracil; gefitinib; irinotecan hydrochloride; leucovorin calcium
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2001-11
- Completion
- Not recorded
- Enrolment
- 22
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionColorectal CancerInterventionfluorouracil; gefitinib; irinotecan hydrochloride; leucovorin calciumPhasePhase 1Registry statusCompletedCetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer
NCT00020917 · start 2001-02
Registered record
- Registry ID
- NCT00020917
- Conditions
- Colorectal Cancer
- Interventions
- cetuximab; fluorouracil; irinotecan hydrochloride; leucovorin calcium
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2001-02
- Completion
- 2004-02
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionColorectal CancerInterventioncetuximab; fluorouracil; irinotecan hydrochloride; leucovorin calciumPhasePhase 2Registry statusCompleted